Combination Therapy with Cisplatin and Activatable Liposomes on Breast Cancer Cells

Area of Science:

• Nanomedicine
• Photodynamic Therapy
• Cancer Therapeutics

Background:

• Cisplatin efficacy is limited by severe side effects and tumor resistance.
• Disulfide-bridged phthalocyanines offer potential to sensitize cancer cells to cisplatin.
• Novel activatable phthalocyanine-loaded liposomes were developed for breast cancer treatment.

Purpose of the Study:

• To synthesize and characterize disulfide-bridged dimeric phthalocyanine-loaded liposomes.
• To evaluate the enhanced anticancer efficacy of cisplatin combined with photodynamic therapy.
• To investigate the potential of this approach in overcoming cisplatin resistance and reducing side effects.

Main Methods:

• Synthesis and characterization of disulfide-bridged dimeric phthalocyanine.
• Encapsulation into liposome nanoparticles and characterization (particle size, PDI).
• In vitro evaluation on MCF-7 breast cancer cells using MTT and flow cytometry.

Main Results:

• Synthesized phthalocyanine showed favorable photodynamic therapy characteristics (absorbance at 685 nm).
• Liposome nanoparticles exhibited suitable characteristics for biomedical applications (167.6 nm size, 0.108 PDI).
• Photodynamic therapy with liposomes significantly enhanced cisplatin's anticancer activity and reduced cell viability (p < 0.01).

Conclusions:

• Activatable liposome nanoparticles containing disulfide-bridged phthalocyanines improve cisplatin-based breast cancer therapy.
• This approach overcomes cisplatin resistance by potentially decreasing intracellular GSH levels.
• It also mitigates serious side effects by enabling lower cisplatin doses.